Souhaitez-vous accéder aux communiqués récents ?

Executive succession plan maintains momentum of recent significant advancesOnconova well-positioned to deliver key milestones in 2019 for both intravenous and oral rigosertib, as well as other...

SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestoneAdvancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions...

NEWTOWN, Pa., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...

Mr. Oler joins Onconova’s management team as Vice President, Corporate Development and General Counsel, after an impactful tenure at Spectrum PharmaceuticalsHiring reflects Onconova’s commitment to...

Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of 34% ORR of 54% and...

Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on...

Dr. Woodman is appointed CMO and Senior Vice President of Research & Development, joining Onconova after multiple accomplishments at NovartisOther recent hires in Clinical and Regulatory Affairs...

Oral presentation on Saturday will feature efficacy and safety data from Expanded Phase 2 trial of rigosertib in combination with AzacitidineThree Poster presentations to feature pharmacokinetics,...

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, November 13, 2018 NEWTOWN, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a...

NEWTOWN, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...